Simplex Trading’s VistaGen Therapeutics VTGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$42.1K Buy
186,400
+172,100
+1,203% +$104K ﹤0.01% 6457
2026
Q1
$8.18K Sell
14,300
-80,000
-85% -$48.6K ﹤0.01% 7516
2025
Q4
$62.4K Buy
94,300
+58,400
+163% +$211K ﹤0.01% 5455
2025
Q3
$127K Sell
35,900
-1,000
-3% -$2.99K ﹤0.01% 5481
2025
Q2
$73K Buy
36,900
+35,800
+3,255% +$81.3K ﹤0.01% 5546
2025
Q1
$2K Sell
1,100
-15,000
-93% -$42.5K ﹤0.01% 8101
2024
Q4
$47K Sell
16,100
-6,800
-30% -$19.1K ﹤0.01% 5947
2024
Q3
$68K Sell
22,900
-72,600
-76% -$248K ﹤0.01% 5607
2024
Q2
$332K Sell
95,500
-22,100
-19% -$95.7K ﹤0.01% 4111
2024
Q1
$620K Buy
117,600
+74,700
+174% +$359K ﹤0.01% 3624
2023
Q4
$215K Buy
42,900
+34,300
+399% +$130K ﹤0.01% 4611
2023
Q3
$45K Buy
8,600
+6,300
+274% +$28K ﹤0.01% 5911
2023
Q2
$4K Buy
+2,300
New +$8.06K ﹤0.01% 8109
2023
Q1
Sell
-400
Closed -$1K 10237
2022
Q4
$1K Sell
400
-2,747
-87% -$10.3K ﹤0.01% 8952
2022
Q3
$14K Buy
3,147
+610
+24% +$6.05K ﹤0.01% 7934
2022
Q2
$66K Buy
2,537
+2,380
+1,516% +$84K ﹤0.01% 6133
2022
Q1
$5K Buy
157
+54
+52% +$2.35K ﹤0.01% 9462
2021
Q4
$6K Buy
+103
New +$6.7K ﹤0.01% 9446

Other funds holding VTGN

Simplex Trading's VTGN Position: Q2 2026 in Review

Simplex Trading reduced its VistaGen Therapeutics (VTGN) stake by 84% in Q2 2026, selling an estimated $45.5K and leaving 14,295 shares worth $3.23K. The position accounts for ﹤0.01% of the portfolio, ranked #8411.

Simplex Trading first reported a position in VTGN in Q2 2022 and has held it in 14 quarters since. The position peaked at $69K in Q3 2024. 49 funds tracked by Wall St. Rank hold VTGN as of Q2 2026.

  • Simplex Trading held 14,295 shares of VistaGen Therapeutics worth $3.23K as of Q2 2026.
  • Simplex Trading sold 75,354 VistaGen Therapeutics shares in Q2 2026, an estimated $45.5K.
  • VistaGen Therapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q2 2026, its #8411 holding.
  • Simplex Trading first reported a position in VistaGen Therapeutics in Q2 2022 and has held it in 14 quarters since.
  • Simplex Trading's VistaGen Therapeutics position peaked at $69K in Q3 2024.
  • 49 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2026.

Based on Simplex Trading's 13F filing for Q2 2026, filed 12 Aug 2026.